AstraZeneca, the maker of Byetta, Bydureon and Bydureon BCise, earned $12.9 billion in the second quarter. Compared to the same quarter in 2023, the company noted a 13% increase in total revenue. AstraZeneca attributed the results to its 18% increase in product sales, but it did not cite the three GLP-1 medications as a factor.
Eli Lilly‘s Mounjaro, Zepbound and Verzenio drove the drugmaker’s 36% increase in revenue. Global sales of Mounjaro, a Type 2 diabetes drug, rose above $3 billion, compared to $979 million in the same period last year. Weight loss drug Zepbound saw $1.2 billion and breast cancer medication Verzenio recorded $1.3 billion in Q2 revenue. Revenue for Trulicity, a Type 2 diabetes drug, was about $1.2 billion.
Novo Nordisk manufactures multiple GLP-1s: Ozempic, Rybelsus, Saxenda, Victoza and Wegovy. The company reported 25% sales growth in the first six months of 2024, with weight loss drug Wegovy logging $21 billion in sales. Sales in obesity care rose 37%, the drugmaker said.
Teva Pharmaceuticals, which launched the first generic GLP-1 in June, said its 16% growth in revenue from generics was partly because of the Victoza generic (liraglutide). Its generics business was a leading driver for its $4.2 billion in earnings.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
